Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAB014 in Wet Age-related Macular Degeneration
NCT03675880Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jun 2018
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab in exudative macular degeneration (6 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Toxicity associated with TAB014 treatment at 28 days. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03675880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675880.